Clinical Trials

Cannabinoid Purification and Scale-Up on Hipersep^® Pilot

For the outstanding efficiency and scalability, high-performance liquid chromatography (HPLC) has been widely used for purification of high-quality APIs and intermediates in the pharmaceutical industry.

PureO₃ Dissolved Ozone Sensor

The new pureO₃ Dissolved Ozone Sensor with Intelligent Sensor Management (ISM^®) technology provides robust, reliable measurement with increased stability in pure water applications.

Clovis Oncology completes target enrollment in ATHENA trial in advanced ovarian cancer

Clovis Oncology announced the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis’ Rubraca (rucaparib), a poly (ADP ribose) polymerase inhibitor (PARP), and Bristol-Myers Squibb’s PD-1 inhibitor, OPDIVO (nivolumab), as front-line maintenance treatment of newly-diagnosed advanced ovarian cancer.

Pfizer announces positive top-line results from JADE TEEN trial of abrocitinib in adolescents with moderate-to-severe atopic dermatitis

Pfizer announced positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 to <18 years of age with moderate to severe atopic dermatitis (AD) who were also on background topical therapy. Both doses of abrocitinib met the co-primary endpoints and were generally well tolerated.

Lyvgen announces clinical trial collaboration with MSD

Lyvgen, a biopharmaceutical company focused on developing innovative immuno-oncology therapeutics, announces that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside of the U.S. and Canada.

Bristol Myers Squibb, UbiVac to assess combination immunotherapy for advanced triple-negative breast cancer

UbiVac has announced clinical trial collaboration Bristol Myers Squibb (BMS) on the combination immunotherapy for advanced triple negative breast cancer.

Relief Therapeutics and NeuroRx expand clinical trial of RLF-100 to all patients with critical Covid-19 and respiratory failure

RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that the phase 2/3 clinical trial evaluating RLF-100 as a treatment for Critical COVID-19 with Respiratory Failure has been expanded to include patients receiving high flow oxygen and noninvasive ventilation (CPAP), in addition to those on ventilators. RLF-100 (Aviptadil) is a patented formulation of synthetic human Vasoactive Intestinal Peptide (VIP), which has been granted Orphan Drug Designation by the US FDA in Acute Respiratory Distress Syndrome and chronic lung diseases.

Eli Lilly’s partner Junshi doses first patient in Covid-19 trial with JS016 investigational medicine

Eli Lilly has announced the commencement of a phase 1 study for its second potential Covid-19 antibody treatment.

Alnylam presents positive phase 3 results from ILLUMINATE-A study of Lumasiran

Alnylam Pharmaceuticals announced positive Phase 3 results from the ILLUMINATE-A study of lumasiran, an investigational RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO) – in development for the treatment of primary hyperoxaluria type 1 (PH1).